Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients

Completed

• Conditions: Chronic Obstructive Pulmonary Disease; Cardiovascular Disease

• Registration Number: NCT01470274
• Lead Sponsor: Norwegian University of Science and Technology

Brief Summary

The primary objective is to establish the safety of the CO-rebreathing method for measuring total blood and plasma volume in CAD patients. The working hypothesis is that the CO-rebreathing method is safe in use with coronary artery disease patients and that it does not cause myocardial ischemia or cardiovascular damage.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-11
• Study First Submitted: 2011-11-09
• Study First Submitted QC: 2011-11-10
• Study First Posted: 2011-11-11
• Primary Completion: 2012-01
• Study Completion: 2012-02
• Status Verified: 2016-07
• Last Update Submitted: 2016-07-28
• Last Update Posted: 2016-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• Stable coronary artery disease
• Stable COPD
• Optimal medication

Exclusion Criteria

• Unstable disease
• co-morbidities

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Norwegian University of Science and Technology; 🇳🇴 Trondheim, Norway